Mesalamine protects against colorectal cancer in inflammatory bowel disease.
about
Mesalamine in the treatment and maintenance of remission of ulcerative colitisCysteinyl leukotriene receptor 1 facilitates tumorigenesis in a mouse model of colitis-associated colon cancer.Dysplasia and cancer in inflammatory bowel disease.Antioxidant properties of mesalamine in colitis inhibit phosphoinositide 3-kinase signaling in progenitor cells.Hyperhomocysteinemia as a potential contributor of colorectal cancer development in inflammatory bowel diseases: a review.Use of thiopurines and risk of colorectal neoplasia in patients with inflammatory bowel diseases: a meta-analysis.5-Aminosalicylates reduce the risk of colorectal neoplasia in patients with ulcerative colitis: an updated meta-analysisChemopreventive effects of 5-amino salicylic acids on inflammatory bowel disease-associated colonic cancer and colonic dysplasia: a meta-analysis.Palmitoylethanolamide Modulates Inflammation-Associated Vascular Endothelial Growth Factor (VEGF) Signaling via the Akt/mTOR Pathway in a Selective Peroxisome Proliferator-Activated Receptor Alpha (PPAR-α)-Dependent Manner.Update on the management of ulcerative colitis: treatment and maintenance approaches focused on MMX(®) mesalamine.Chemoprevention of gastrointestinal cancer: the reality and the dream.Does aspirin or non-aspirin non-steroidal anti-inflammatory drug use prevent colorectal cancer in inflammatory bowel disease?Human intestinal microbiota: cross-talk with the host and its potential role in colorectal cancer.5-aminosalicylic acid is not protective against colorectal cancer in inflammatory bowel disease: a meta-analysis of non-referral populations.The role of chemoprevention of colorectal cancer with 5-aminosalicylates in ulcerative colitis.The surgical treatment of inflammatory bowel disease-associated dysplasia.Colorectal cancer in inflammatory bowel disease: results of the 3rd ECCO pathogenesis scientific workshop (I).Mesalamine, but Not Sulfasalazine, Reduces the Risk of Colorectal Neoplasia in Patients with Inflammatory Bowel Disease: An Agent-specific Systematic Review and Meta-analysis.Randomized clinical trial of prevention of seroma formation after mastectomy by local methylprednisolone injection.Chemoprevention of colorectal cancer in inflammatory bowel disease.Chemopreventive effects of 5-aminosalicylic acid on inflammatory bowel disease-associated colorectal cancer and dysplasia: a systematic review with meta-analysis.Systematic review with meta-analysis: use of 5-aminosalicylates and risk of colorectal neoplasia in patients with inflammatory bowel disease.Persistence to oral 5-aminosalicylate therapy for inflammatory bowel disease in Australia.DUOX2 and DUOXA2 form the predominant enzyme system capable of producing the reactive oxygen species H2O2 in active ulcerative colitis and are modulated by 5-aminosalicylic acid.Systematic review with meta-analysis: thiopurines decrease the risk of colorectal neoplasia in patients with inflammatory bowel disease.
P2860
Q26865546-7D64E9D8-6381-4C36-B3F5-7EEA6D2A3989Q33798596-2AA42021-49B0-40E8-849A-DB86B6814EAEQ33817401-C87184E8-3DBC-40A5-9EB2-84585C577A1DQ34836490-2DF48241-5DBC-4D15-9019-F29918E06188Q35012018-6FDDE280-7274-4AAA-98D8-7BA966E06EE2Q35060557-A42689DD-3A1E-4AF4-A19F-4E9518D7BC46Q35142116-D659FA13-6A0B-4EA7-8B40-E943D5B3EEC5Q35619921-4CFF0241-C888-4624-AFC7-AB2552D43C45Q36027964-FE12BC19-48C5-4D27-B9D5-CCF083F0E2AFQ36144377-966A5ABC-05B5-48E6-A79D-F91E3B035F35Q36715105-BB2E4E3B-4F40-4642-9342-767682F2DA0FQ36747550-59BDBCF2-3B4B-4BF4-9829-76375D43A9B0Q37793208-A2074136-4068-4EC6-B93B-D099099B670BQ38023149-E392D3DD-4B3E-496E-A51E-FE534D6FB2D8Q38064743-3A78E150-0C31-4E96-80F7-E070A9CB1560Q38103624-08B53227-709C-446D-9B0D-A3C8899F3959Q38105801-8F15C92A-2B2C-4BCC-BE2A-CCA439F9B09AQ38571099-3F4A840A-CDDD-4096-A62E-D16B1F379D31Q38984262-ED0EF16D-9FF2-49F0-88B5-691802D3D3E4Q39016806-C9E61CC6-202A-4DC8-AAD2-47F810868ADEQ39025709-CCDBAD01-1028-4A52-A8FB-A3FA6CB133E3Q39162961-EBB29DE8-B725-44F1-B3B8-7F9A29F62888Q43993221-D8781663-9A08-4DC7-9DA0-00015B381D92Q46215033-7E7E2ABA-9E0B-455B-BAC4-1D0547E3F324Q48180321-872A0654-8956-48DC-A53B-CD082ED583A2
P2860
Mesalamine protects against colorectal cancer in inflammatory bowel disease.
description
2009 nî lūn-bûn
@nan
2009 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
Mesalamine protects against colorectal cancer in inflammatory bowel disease.
@ast
Mesalamine protects against colorectal cancer in inflammatory bowel disease.
@en
Mesalamine protects against colorectal cancer in inflammatory bowel disease.
@nl
type
label
Mesalamine protects against colorectal cancer in inflammatory bowel disease.
@ast
Mesalamine protects against colorectal cancer in inflammatory bowel disease.
@en
Mesalamine protects against colorectal cancer in inflammatory bowel disease.
@nl
prefLabel
Mesalamine protects against colorectal cancer in inflammatory bowel disease.
@ast
Mesalamine protects against colorectal cancer in inflammatory bowel disease.
@en
Mesalamine protects against colorectal cancer in inflammatory bowel disease.
@nl
P2093
P2860
P921
P1476
Mesalamine protects against colorectal cancer in inflammatory bowel disease.
@en
P2093
Ann L Silverman
Chetan Pai
Jeffrey Tang
Omar Sharif
P2860
P2888
P304
P356
10.1007/S10620-009-0942-X
P577
2009-08-25T00:00:00Z
P6179
1039695817